利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

112 条记录 (耗时 0.035 秒)

    Megakaryocytic protein tyrosine kinases
    1.
    发明授权
    Megakaryocytic protein tyrosine kinases 失效
    巨核细胞蛋白酪氨酸激酶

    公开(公告)号：US06326469B1

    公开(公告)日：2001-12-04

    申请号：US08426509

    申请日：1995-04-21

    申请人： Axel Ullrich ,  Mikhail Gishizky ,  Irmingard Sures

    发明人： Axel Ullrich ,  Mikhail Gishizky ,  Irmingard Sures

    IPC分类号： C07K1700

    CPC分类号： C12N9/1205 ,  A61K38/00 ,  C07K2319/00 ,  C12N2799/027

    摘要： The present invention relates to novel cytoplasmic tyrosine kinases isolated from megakaryocytes (megakaryocyte kinases or MKKs) which are involved in cellular signal transduction pathways and to the use of these novel proteins in the diagnosis and treatment of disease. The present invention further relates to specific megakaryocyte kinases, designated MKK1, MKK2 and MKK3, and their use as diagnostic and therapeutic agents.

    摘要翻译： 本发明涉及从涉及细胞信号转导途径的巨核细胞（巨核细胞激酶或MKK）分离的新型细胞质酪氨酸激酶以及这些新型蛋白在诊断和治疗疾病中的用途。 本发明还涉及称为MKK1，MKK2和MKK3的特异性巨核细胞激酶及其作为诊断和治疗剂的用途。

    Novel megakaryocytic protein tyrosine kinase 1
    2.
    发明申请
    Novel megakaryocytic protein tyrosine kinase 1 审中-公开
    新型巨核细胞蛋白酪氨酸激酶1

    公开(公告)号：US20060263877A1

    公开(公告)日：2006-11-23

    申请号：US11415072

    申请日：2006-05-02

    申请人： Axel Ullrich ,  Mikhail Gishizky ,  Irmingard Sures

    发明人： Axel Ullrich ,  Mikhail Gishizky ,  Irmingard Sures

    IPC分类号： C12N5/06 ,  C07K16/40

    CPC分类号： C12N9/1205 ,  A61K38/00 ,  C07K16/40 ,  C07K2319/00 ,  C12N2799/027 ,  C12P21/02

    摘要： The present invention relates to novel cytoplasmic tyrosine kinases isolated from megakaryocytes (megakaryocyte kinases or MKKs) which are involved in cellular signal transduction pathways and to the use of these novel proteins in the diagnosis and treatment of disease. The present invention further relates to specific megakaryocyte kinases, designated MKK1, MKK2 and MKK3, and their use as diagnostic and therapeutic agents.

    摘要翻译： 本发明涉及从涉及细胞信号转导途径的巨核细胞（巨核细胞激酶或MKK）分离的新型细胞质酪氨酸激酶以及这些新型蛋白在诊断和治疗疾病中的用途。 本发明还涉及称为MKK1，MKK2和MKK3的特异性巨核细胞激酶及其作为诊断和治疗剂的用途。

    Megakaryocytic protein tyrosine kinase I
    3.
    发明授权
    Megakaryocytic protein tyrosine kinase I 失效
    巨核细胞蛋白酪氨酸激酶I

    公开(公告)号：US07037677B2

    公开(公告)日：2006-05-02

    申请号：US09977260

    申请日：2001-10-16

    申请人： Axel Ullrich ,  Mikhail Gishizky ,  Irmingard Sures

    发明人： Axel Ullrich ,  Mikhail Gishizky ,  Irmingard Sures

    IPC分类号： C12P21/06 ,  C12P21/04 ,  C12N15/00 ,  C07H21/04

    CPC分类号： C12N9/1205 ,  A61K38/00 ,  C07K16/40 ,  C07K2319/00 ,  C12N2799/027 ,  C12P21/02

    摘要： The present invention relates to novel cytoplasmic tyrosine kinases isolated from megakaryoctyes (megakaryocyte kinases or MKKs) which are involved in cellular signal transduction pathways and to the use of these novel proteins in the diagnosis and treatment of disease. The present invention further relates to specific megakaryocyte kinases, designated MKK1, MKK2, and MKK3, and their use as diagnostic and therapeutic agents.

    摘要翻译： 本发明涉及从参与细胞信号转导途径的巨核细胞（megakaryocyte kinases or MKKs）分离的新型细胞质酪氨酸激酶以及这些新型蛋白在诊断和治疗疾病中的应用。 本发明还涉及称为MKK1，MKK2和MKK3的特异性巨核细胞激酶及其作为诊断和治疗剂的用途。

    Megakaryocytic protein tyrosine kinase I
    4.
    发明授权
    Megakaryocytic protein tyrosine kinase I 失效
    巨核细胞蛋白酪氨酸激酶I

    公开(公告)号：US06908984B2

    公开(公告)日：2005-06-21

    申请号：US09977261

    申请日：2001-10-16

    申请人： Axel Ullrich ,  Mikhail Gishizky ,  Irmingard Sures

    发明人： Axel Ullrich ,  Mikhail Gishizky ,  Irmingard Sures

    IPC分类号： A61K38/00 ,  C12N9/12 ,  C12P21/04 ,  C07K14/00 ,  A61K39/00

    CPC分类号： C12N9/1205 ,  A61K38/00 ,  C07K2319/00 ,  C12N2799/027

    摘要： The present invention relates to novel cytoplasmic tyrosine kinases isolated from megakaryocytes (megakaryocyte kinases or MKKs) which are involved in cellular signal transduction pathways and to the use of these novel proteins in the diagnosis and treatment of disease. The present invention further relates to specific megakaryocyte kinases, designated MKK1, MKK2, and MKK3, and their use as diagnostic and therapeutic agents.

    摘要翻译： 本发明涉及从涉及细胞信号转导途径的巨核细胞（巨核细胞激酶或MKK）分离的新型细胞质酪氨酸激酶以及这些新型蛋白在诊断和治疗疾病中的用途。 本发明还涉及称为MKK1，MKK2和MKK3的特异性巨核细胞激酶及其作为诊断和治疗剂的用途。

    Nucelotide encoding megakaryocytic protein tyrosine kinases
    5.
    发明授权
    Nucelotide encoding megakaryocytic protein tyrosine kinases 失效
    Nuclotide编码巨核细胞蛋白酪氨酸激酶

    公开(公告)号：US06506578B1

    公开(公告)日：2003-01-14

    申请号：US08232545

    申请日：1994-04-22

    申请人： Axel Ullrich ,  Mikhail Gishizky ,  Irman Gard Sures

    发明人： Axel Ullrich ,  Mikhail Gishizky ,  Irman Gard Sures

    IPC分类号： C12P2106

    CPC分类号： C12N9/1205 ,  A61K38/00 ,  C07K16/40 ,  C07K2319/00 ,  C12N2799/027 ,  C12P21/02

    摘要： The present invention relates to novel cytoplasmic tyrosine kinases isolated from megakaryocytes (megakaryocyte kinases or MKKs) which are involved in cellular signal transduction pathways and to the use of these novel proteins in the diagnosis and treatment of disease. The present invention further relates to specific megakaryocyte kinases, designated MKK1, MKK2 and MKK3, and their use as diagnostic and therapeutic agents.

    摘要翻译： 本发明涉及从涉及细胞信号转导途径的巨核细胞（巨核细胞激酶或MKK）分离的新型细胞质酪氨酸激酶以及这些新型蛋白在诊断和治疗疾病中的用途。 本发明还涉及称为MKK1，MKK2和MKK3的特异性巨核细胞激酶及其作为诊断和治疗剂的用途。

    USE OF INHIBITORS FOR THE TREATMENT OF RTK-HYPERFUNCTION-INDUCED DISORDERS, PARTICULARLY CANCER
    10.
    发明申请
    USE OF INHIBITORS FOR THE TREATMENT OF RTK-HYPERFUNCTION-INDUCED DISORDERS, PARTICULARLY CANCER 有权
    使用抑制剂治疗RTK超敏感性疾病，特别是癌症

    公开(公告)号：US20100184686A1

    公开(公告)日：2010-07-22

    申请号：US12689672

    申请日：2010-01-19

    申请人： Axel Ullrich ,  Johannes Bange ,  Pjotr Knyazev

    发明人： Axel Ullrich ,  Johannes Bange ,  Pjotr Knyazev

    IPC分类号： A61K38/17 ,  C07K14/71 ,  C07H21/04 ,  C07K16/28 ,  A61P35/04 ,  A61P35/00 ,  C12Q1/68 ,  C12Q1/48

    CPC分类号： C07K14/71 ,  A61K38/00 ,  G01N33/574

    摘要： The present invention concerns the use of inhibitors for the treatment and/or prophylaxis of diseases which are the consequence of increased receptor tyrosine kinase activity, particularly cancer. The use is particularly directed towards inhibition or lowering of the overexpression and/or altered activity of receptor tyrosine kinases (RTKs). In particular, this altered activity of receptor tyrosine kinase can be triggered by a mutation of FGFR-4, wherein this mutation is in particular a point mutation in the transmembrane domain of FGFR-4 and leads to an exchange of a hydrophobic amino acid for a hydrophilic amino acid. The invention further concerns the use of an inhibitor directed against FGFR-4, for the treatment and/or prophylaxis of cancer. Furthermore, the invention concerns a mutated FGFR-4, which leads to over-expression and/or altered activity in cells. Finally, the invention concerns a DNA and RNA sequence of a mutated FGFR-4 molecule. Finally, in addition the invention concerns a pharmaceutical composition, containing the inhibitor as described above and further a diagnostic and screening procedure.

    摘要翻译： 本发明涉及抑制剂用于治疗和/或预防由于受体酪氨酸激酶活性增加，特别是癌症引起的疾病的用途。 该用途特别涉及抑制或降低受体酪氨酸激酶（RTK）的过表达和/或改变的活性。 特别地，受体酪氨酸激酶的这种改变的活性可以由FGFR-4的突变引发，其中该突变特别是FGFR-4的跨膜结构域中的点突变，并导致疏水性氨基酸的交换 亲水氨基酸。 本发明还涉及使用针对FGFR-4的抑制剂来治疗和/或预防癌症。 此外，本发明涉及突变的FGFR-4，其导致细胞中过度表达和/或改变的活性。 最后，本发明涉及突变的FGFR-4分子的DNA和RNA序列。 最后，本发明还涉及包含如上所述的抑制剂的药物组合物，并进一步进行诊断和筛选程序。